Premium
Classification and characteristics of interferon‐related diabetes mellitus in Japan
Author(s) -
Muraishi Kazuhisa,
Sasaki Yuko,
Kato Tomoko,
Inada Chizuko,
Tajiri Yuji,
Yamada Kentaro
Publication year - 2011
Publication title -
hepatology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.123
H-Index - 75
eISSN - 1872-034X
pISSN - 1386-6346
DOI - 10.1111/j.1872-034x.2010.00753.x
Subject(s) - medicine , diabetes mellitus , type 2 diabetes , type 1 diabetes , ribavirin , interferon , human leukocyte antigen , immunology , endocrinology , antigen , virus , hepatitis c virus
Aim: The aim of this study was to assess the classification and clinical characteristics of interferon (IFN)‐related diabetes. Methods: Cases with IFN‐related diabetes in Japan were retrieved through web search engines for medical literature until July in 2009, and unreported data were obtained from the authors by letter or e‐mail. Results: We collected 143 cases with IFN‐related diabetes consisting of 104 type 1 diabetes including 4 own cases, and 39 non‐autoimmune type 2‐like diabetes. We found a marked increase in IFN‐related type 1 diabetes for these 3 years. In contrast, no increase was observed in IFN‐related type 2‐like diabetes in the literature. Polyethylene glycol (PEG)‐IFN and ribavirin had been more frequently used in patients with type 1 diabetes than in patients with type 2‐like diabetes. The age of diabetes onset was comparable between type 1 and type 2‐like diabetes, while the ratio of male patients was higher and the latency before diabetes was shorter in type 2‐like diabetes. Patients with IFN‐related type 1 diabetes had HLA types susceptible to Japanese type 1 diabetic patients, and a high positive rate of GAD antibodies. Conclusion: Potent combination therapy with PEG‐IFN and ribavirin is likely associated with the increase in IFN‐related type 1 diabetes. The combined measurement of GAD antibody and HLA‐typing could be an effective strategy to predict the onset of type 1 diabetes associated with IFN therapy.